FY2026 EPS Estimates for Indivior Raised by Northland Capmk

Indivior PLC (NASDAQ:INDV) – Equities research analysts at Northland Capmk boosted their FY2026 earnings estimates for Indivior in a research report issued on Thursday, October 30th. Northland Capmk analyst C. Byrnes now anticipates that the company will post earnings per share of $2.25 for the year, up from their previous estimate of $2.00. The consensus estimate for Indivior’s current full-year earnings is $1.22 per share.

A number of other research firms also recently issued reports on INDV. Jefferies Financial Group assumed coverage on shares of Indivior in a research note on Tuesday, July 22nd. They issued a “buy” rating and a $20.00 price target on the stock. Weiss Ratings reissued a “hold (c)” rating on shares of Indivior in a research note on Friday. Northland Securities set a $40.00 price target on shares of Indivior in a research note on Friday. HC Wainwright boosted their price target on shares of Indivior from $28.00 to $35.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. Finally, Craig Hallum reissued a “buy” rating and issued a $41.00 price target on shares of Indivior in a research note on Friday. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $32.17.

Indivior Trading Up 6.2%

Indivior stock opened at $31.20 on Monday. Indivior has a 12-month low of $7.62 and a 12-month high of $31.63. The stock has a market cap of $4.30 billion, a P/E ratio of 50.32 and a beta of 0.70. The company has a 50-day moving average price of $24.38 and a 200 day moving average price of $18.42.

Indivior (NASDAQ:INDV) last released its quarterly earnings data on Thursday, October 30th. The company reported $0.72 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.34. Indivior had a net margin of 6.65% and a negative return on equity of 86.28%. The firm had revenue of $314.00 million during the quarter, compared to analysts’ expectations of $257.66 million. Indivior has set its FY 2025 guidance at EPS.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Landscape Capital Management L.L.C. grew its holdings in shares of Indivior by 78.1% in the first quarter. Landscape Capital Management L.L.C. now owns 140,137 shares of the company’s stock valued at $1,336,000 after purchasing an additional 61,455 shares in the last quarter. Acadian Asset Management LLC acquired a new position in shares of Indivior in the first quarter valued at approximately $6,328,000. State of New Jersey Common Pension Fund D acquired a new position in shares of Indivior in the second quarter valued at approximately $262,000. Vanguard Group Inc. grew its holdings in shares of Indivior by 1.6% in the first quarter. Vanguard Group Inc. now owns 4,631,221 shares of the company’s stock valued at $43,765,000 after purchasing an additional 71,539 shares in the last quarter. Finally, Jane Street Group LLC grew its holdings in shares of Indivior by 2,597.9% in the first quarter. Jane Street Group LLC now owns 995,013 shares of the company’s stock valued at $9,327,000 after purchasing an additional 958,132 shares in the last quarter. Institutional investors and hedge funds own 60.33% of the company’s stock.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.